ESC 23: Hot Line & Late-breaking Science Video Collection
Published: 04 August 2023
-
Views:
5039 -
Likes:
7
-
Views:
5039 -
Likes:
7
-
Up Next
-
3m 59sPart 4 | Session 7 HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency
-
4m 49sPart 4 | Session 8 SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation
-
4m 41s
-
4m 12sPart 4 | Session 10 ILUMIEN IV: OCT Vs Angiography
-
5m 20sPart 4 | Session 11 ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure
-
5m 23sPart 4 | Session 12 MULTISTARS AMI: Immediate Vs Staged PCI in STEMI and MVD
-
6m 3sPart 4 | Session 13 OCT Vs IVUS Vs Angiography Guidance
-
4m 5sPart 4 | Session 14 OCTOBER: OCT-Guided or Angiography-Guided PCI in Complex Bifurcation Lesions
-
2m 55sPart 4 | Session 15 DANPACE II: Reducing Atrial Pacing in Sinus Node Disease
-
6m 43sPart 4 | Session 16 COP-AF: Colchicine for Perioperative AF
-
4m 33sPart 4 | Session 17 CASTLE-HTx: Catheter Ablation for AF in Pts with Heart Failure
-
4m 53sPart 4 | Session 18 OCTIVUS: OCT Vs IVUS-Guided Percutaneous Coronary Intervention
-
4m 56sPart 4 | Session 19 PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure
-
4m 16s
-
4m 8sPart 4 | Session 21 ONCO DVT: Optimal Duration of DOAC Therapy for IDDVT Patients with Cancer
-
4m 39sPart 4 | Session 22 ATTRibute-CM Trial
-
5m 21sPart 4 | Session 23 RIGHT: Post-PPCI Anticoagulation in STEMI Patients
-
6m 1sPart 4 | Session 24 ARAMIS: Anakinra versus Placebo in Acute Myocarditis
-
4m 9s
-
6m 42sPart 5 | Session 1 Takeaways from ESC 2023 with Dr Cvijic & Dr Grapsa
-
9m 47sPart 5 | Session 2 Takeaways from ESC 2023 with Dr Al-Lamee, Dr Colleran & Dr Paradies
-
3m 33sPart 6 | Session 1 Leadership in Guidelines and Cardiovascular Education with Dr Robert Byrne
-
59sPart 6 | Session 2 Patient Care and Treatment Strategies with Dr Myeong-Ki Hong
-
2m 2s
-
1m 27sPart 6 | Session 4 Intersection of Politics and Medicine with Dr Luengo-Fernandez
-
1m 24sPart 6 | Session 5 Choosing Cardiology and Advice to Researchers with Dr Robert Mentz
-
1m 10sPart 6 | Session 6 Leadership in the Context of Clinical Trials with Dr Michelle O'Donoghue
-
46sPart 6 | Session 7 Trials to Watch Out For with Dr Masahiro Natsuaki
-
49s
-
1m 2sPart 6 | Session 9 Emerging Topics in Electrophysiology with Dr Tobias Reichlin
-
1m 23sPart 6 | Session 10 Key Trials and Data from ESC 23 with Dr Ziad Ali
-
36s
-
58sPart 6 | Session 12 Inspiring Teams with Prof Barbara Stahli
-
2m 21sPart 6 | Session 13 Advice for Early-Career Researchers from Dr Gregg Stone
-
48sPart 6 | Session 14 New Technologies in Electrophysiology with Dr Mads Brix Kronborg
-
1m 25sPart 6 | Session 15 Considering Unmet Needs in Patient Care with Dr Duk-Woo Park
-
59sPart 6 | Session 16 Improving Clinical Practice with Dr Do-Yoon Kang
-
1m 28sPart 6 | Session 17 Contributing to the Guidelines with Dr Jozine Ter Maaten
-
2m 41sPart 6 | Session 18 Emerging Trends in Amyloidosis with Prof Julian Gillmore
-
30sPart 6 | Session 19 Working With Role Models with Dr Yan Yan
-
1m 17sPart 6 | Session 20 The Importance of Mentorship with Dr Giles Montalescot
-
1m 24sPart 6 | Session 21 Personalised Medicine & Team Approach With Dr Christian Sohns
-
1m 51sPart 6 | Session 22 Advancement of EP & Adapting New Approaches With Dr Philipp Sommer
-
2m 14s
-
47m 55sPart 1 | Session 1 ESC 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 31sPart 1 | Session 2 ESC 23 Late-breaking Science Preview Joost Daemen, Nicolas M Van Mieghem
-
13m 31sPart 2 | Session 1 The ECLS-Shock Trial Harriette Van Spall, Holger Thiele
-
13m 24sPart 2 | Session 2 The STEP HFpEF Trial Harriette Van Spall, Mikhail Kosiborod
-
9m 37sPart 2 | Session 3 The RECORD MI Registry Harriette Van Spall, Javed Butler
-
30m 23sPart 2 | Session 4 Heart Failure at ESC 2023: Recapitulations, Postulations, Predictions Milton Packer, Harriette Van Spall
-
13m 28sPart 3 | Session 1 Day 1 Highlights: New Guidelines, STEP-HFpEF, COP-AF Mirvat Alasnag, Khaled Al-Shaibi
-
16m 34sPart 3 | Session 2 Day 2 Highlights: BUDAPEST-CRT, FIRE, ECLS-Shock, STOPDAPT-3 Mirvat Alasnag, Khaled Al-Shaibi
-
13m 51sPart 3 | Session 3 Day 3 Highlights: OCT Trials, MULTISTARS-AMI, ATTRibute-CM Mirvat Alasnag, Khaled Al-Shaibi
-
8m 3sPart 3 | Session 4 Day 4 Highlights: OPT-BIRISK & NITRATE-CIN Mirvat Alasnag, Khaled Al-Shaibi
-
6m 46sPart 4 | Session 1 New Guidelines For the Management of Acute Coronary Syndromes Robert A Byrne
-
3m 42sPart 4 | Session 2 NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE Paulus Kirchhof
-
3m 42sPart 4 | Session 3 LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients Myeong-Ki Hong
-
6m 14sPart 4 | Session 4 Economic Burden of Cardiovascular Disease in the EU Ramón Luengo-Fernández
-
3m 22sPart 4 | Session 5 OCEAN(a)-DOSE: Olpasiran in Patients with Atherosclerotic CVD and Elevated LP(a) Michelle O'Donoghue
Overview
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
- Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
- Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
- We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Daily Wrap-Ups with Dr Alasnag & Dr Al-Shaibi
Part 4
Expert Interviews
Part 5
Women as One & Radcliffe Cardiology Presents
Part 6
Behind the Heart
About the episode
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at one year in high bleeding risk (HBR) patients. The STOPDAPT-3 Study (Kyoto University) aimed to explore the potential benefits of prasugrel monotherapy (without aspirin) when compared with 1-month of DAPT with aspirin and prasugrel in reducing bleeding events post-percutaneous coronary intervention (PCI) in HBR and acute coronary syndrome (ACS) patients.
6002 patients were enrolled in the trial, where major bleeding was defined as BARC criteria 3 or 5. Results suggested that prasugrel monotherapy did not attest superiority for the reduction of major bleeding events within 1 month after PCI, and was associated with an excess of coronary events including sub-acute stent thrombosis.
Questions:
- What is the background to this trial?
- 2. What was the study design, patient population and outcome measures?
- What are the key results presented at ESC?
- What is the applicability to populations outside of Japan?
- What are the take-home messages?
- What are the next steps?
Recorded on-site at ESC Congress 2023, Amsterdam.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles
Comments